Imaging Biometrics Ltd (LSE:IBAI, FRA:5Y1) told shareholders its commercial momentum is 'genuine and measurable' as it unveiled a substantially upgraded version of its clinical collaboration platform ahead of its annual meeting and said it was firmly on the road to profitability. Reprising progress to date, the quantitative neuroimaging software and organ-on-a-chip group said it has launched IB Nimble 2, a new iteration of its secure mobile and web-based platform designed to support tumour board discussions, complex disease management, and emergent care settings.